Evolutionary Genomics, Inc. (FNAM) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerEvolutionary Genomics, Inc. (FNAM) trades at $0.0002. Evolutionary Genomics, Inc. is a biotechnology company focused on identifying beneficial genes in humans, animals, and crops. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for FNAM: FNAM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Evolutionary Genomics, Inc. (FNAM) Healthcare & Pipeline Overview
Evolutionary Genomics, Inc. specializes in genomic research to enhance agricultural traits through its proprietary Adapted Traits Platform, catering to a diverse clientele that includes governmental and commercial entities.
What Is the Investment Thesis for FNAM?
Evolutionary Genomics, Inc. presents a unique value proposition through its Adapted Traits Platform, which addresses critical agricultural challenges such as food security and climate resilience. The global agricultural biotechnology market is projected to reach $50 billion by 2027, driven by increasing demand for genetically enhanced crops. Evolutionary Genomics’ focus on enhancing traits like drought tolerance and pest resistance positions it strategically within this growing market. The company's partnerships with governmental and non-profit organizations provide a stable revenue stream and enhance its credibility in the industry. However, the company faces risks associated with regulatory approvals and competition from larger biotechnology firms, which could impact its growth trajectory. Investors may want to evaluate these factors as they assess the company's potential for long-term success.
Based on FMP financials and quantitative analysis
FNAM Key Highlights
Market Cap: $0.00B, indicating a nascent stage with potential for growth as the biotechnology sector expands.
- Beta: -0.13, suggesting low volatility compared to the broader market.
- No dividend yield, reflecting a focus on reinvestment for growth.
- Small team of 2 employees, enabling agile decision-making and innovation.
- Established in 1990, showcasing over three decades of expertise in the biotechnology field.
Who Are FNAM's Competitors?
FNAM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MON Monument Circle Acquisition Corp. | $10.07 | +0.20% | — | |
| SYT SYLA Technologies Co., Ltd. American Depositary Shares | $2.26 | 0.00% | — | |
| RLYB Rallybio Corporation | $16.65 | +0.06% | $88.5M | 82 5-pillar |
| ICCC ImmuCell Corporation | $10.24 | -0.10% | $93.6M | 78 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.08 | -1.21% | $170M | 75 5-pillar |
| NAGE Niagen Bioscience Inc | $2.44 | +0.41% | $190M | 70 5-pillar |
| QTTB Q32 Bio Inc. | $8.45 | -2.31% | $252M | 67 5-pillar |
| CLYM Climb Bio, Inc. | $8.81 | -13.54% | $506M | 67 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are FNAM's Key Strengths?
Proprietary Adapted Traits Platform for identifying beneficial genes.
- Established presence in the biotechnology sector since 1990.
- Diverse clientele including government and commercial entities.
What Are FNAM's Weaknesses?
Limited workforce of only 2 employees, which may restrict operational capacity.
- No current revenue generation reported, indicating early-stage development.
- Dependence on external partnerships for funding and growth.
What Are the Key Risks for FNAM?
Financial-distress signal — its Altman Z-Score of -14.34 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles that could delay product development and market entry.
- Competition from larger biotechnology firms with more resources.
- Market volatility affecting funding and investment in agricultural biotechnology.
What Are FNAM's Competitive Advantages?
- Proprietary technology in the form of the Adapted Traits Platform.
- Established relationships with governmental and non-profit organizations.
- Expertise in identifying beneficial genes, providing a competitive edge.
What Does FNAM Do?
Evolutionary Genomics, Inc. was founded in 1990 and is headquartered in Castle Rock, Colorado. The company focuses on the investigation and identification of beneficial genes found in humans, various animal species, and commercial agricultural crops. Its proprietary Adapted Traits Platform is an advanced technological system designed to pinpoint specific genetic markers that can enhance desirable characteristics in plants. The platform aims to improve various traits, including increased crop yield, elevated sugar content, greater biomass production, enhanced drought tolerance, and superior resistance to pests and diseases. Evolutionary Genomics, Inc. serves a wide array of clients, including governmental organizations, non-profit foundations, and commercial enterprises, thereby establishing a diverse market presence. The company’s commitment to advancing agricultural biotechnology positions it as a key player in the sector, particularly as global demand for food security and sustainable agricultural practices continues to rise. With a small team of two employees, Evolutionary Genomics remains agile and focused on its mission to leverage genetic insights for agricultural advancements.
What Products and Services Does FNAM Offer?
- Investigate and identify beneficial genes in humans, animals, and commercial crops.
- Develop the Adapted Traits Platform for pinpointing genetic markers.
- Enhance agricultural traits such as yield, drought tolerance, and pest resistance.
- Serve a diverse clientele including governmental organizations and commercial enterprises.
- Focus on sustainable agricultural practices through genetic research.
How Does FNAM Make Money?
- Generate revenue through partnerships with governmental and non-profit organizations.
- Offer consulting services related to genetic research and agricultural enhancements.
- Develop proprietary technology for identifying beneficial genetic traits.
What Industry Does FNAM Operate In?
The biotechnology industry, particularly in the agricultural sector, is experiencing significant growth, driven by advancements in genetic research and increasing demand for sustainable farming practices. The global agricultural biotechnology market is expected to grow at a CAGR of 10% from 2022 to 2027, reaching approximately $50 billion. Evolutionary Genomics, Inc. is well-positioned within this landscape, focusing on enhancing crop traits that address critical issues such as climate change and food security. The competitive landscape includes larger firms with more resources, but Evolutionary Genomics' specialized focus on beneficial gene identification offers a niche advantage.
Who Are FNAM's Key Customers?
- Governmental organizations focused on agricultural research.
- Non-profit foundations supporting sustainable agriculture.
- Commercial enterprises in the agricultural sector seeking genetic enhancements.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Evolutionary Genomics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Castle Rock, US. FNAM has traded publicly since 2011.
Key Financial Metrics
Return on equity for Evolutionary Genomics, Inc. stands at 64.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -82.2%, showing how much profit it generates from its asset base. A current ratio of 3.92 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Evolutionary Genomics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -14.34 places it in the distress zone, a signal of elevated financial risk.
FNAM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
FNAM Latest News
No recent news available for FNAM.
FNAM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for FNAM.
Price Targets
Wall Street price target analysis for FNAM.
FNAM MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for FNAM; grades run from A+ (80-100) to F (below 30).
Leadership: Steve Warnecke
CEO
Steve Warnecke has been leading Evolutionary Genomics, Inc. since its inception in 1990. With a background in genetic research and biotechnology, he has been instrumental in developing the company's proprietary Adapted Traits Platform. Warnecke holds a degree in biology and has extensive experience in agricultural biotechnology.
Track Record: Under Steve Warnecke's leadership, Evolutionary Genomics has established itself as a key player in the biotechnology sector, focusing on sustainable agricultural practices. His strategic vision has led to the development of innovative solutions that address critical agricultural challenges.
FNAM OTC Market Information
The OTC Other tier includes companies that do not meet the listing requirements of major exchanges like NYSE or NASDAQ. This tier allows for trading of smaller companies that may have limited financial disclosures and lower liquidity.
- OTC Tier: OTC Other
- Limited financial disclosures may lead to uncertainty regarding the company's performance.
- Lower liquidity on the OTC market can result in higher volatility.
- Potential regulatory scrutiny affecting smaller biotech firms.
- Verify the company's financial health and operational metrics.
- Assess the credibility of management and their track record.
- Review any existing partnerships and contracts.
- Investigate the competitive landscape and market positioning.
- Examine the regulatory environment affecting the biotechnology sector.
- Established presence in the biotechnology industry since 1990.
- Development of proprietary technology in agricultural genetics.
- Diverse client base including governmental and non-profit organizations.
FNAM Healthcare Stock FAQ
What are the main risks for FNAM?
Evolutionary Genomics, Inc. faces several risks, including regulatory hurdles that could impede product development and market entry. Additionally, the company competes with larger biotechnology firms that have more resources, which could impact its market position.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited financial disclosures may affect the overall assessment of the company's performance.